Johnson & Johnson $JNJ Shares Sold by Heritage Wealth Advisors

Heritage Wealth Advisors reduced its position in Johnson & Johnson (NYSE:JNJ) by 0.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 336,611 shares of the company’s stock after selling 1,509 shares during the period. Johnson & Johnson accounts for about 2.4% of Heritage Wealth Advisors’ holdings, making the stock its 12th biggest holding. Heritage Wealth Advisors’ holdings in Johnson & Johnson were worth $51,417,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Traub Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $190,000. Perennial Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 12.3% during the second quarter. Perennial Investment Advisors LLC now owns 6,026 shares of the company’s stock worth $921,000 after buying an additional 659 shares during the period. Pin Oak Investment Advisors Inc. raised its stake in Johnson & Johnson by 3.7% during the 2nd quarter. Pin Oak Investment Advisors Inc. now owns 7,919 shares of the company’s stock valued at $1,313,000 after acquiring an additional 280 shares during the last quarter. Diversified Portfolios Inc. purchased a new stake in shares of Johnson & Johnson during the second quarter worth approximately $264,000. Finally, Wescott Financial Advisory Group LLC increased its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Wescott Financial Advisory Group LLC now owns 19,329 shares of the company’s stock valued at $2,953,000 after buying an additional 110 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

JNJ opened at $200.10 on Wednesday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $200.30. The stock has a market cap of $482.11 billion, a P/E ratio of 19.31, a P/E/G ratio of 2.19 and a beta of 0.38. The stock’s 50 day simple moving average is $186.69 and its 200 day simple moving average is $170.77. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. Johnson & Johnson’s payout ratio is presently 50.19%.

Wall Street Analyst Weigh In

JNJ has been the topic of several analyst reports. HSBC lifted their target price on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Scotiabank began coverage on Johnson & Johnson in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price target for the company. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.